Showing 4921-4930 of 5646 results for "".
- Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-1-clinical-trial-of-otx-csi-for-treatment-of-dry-eye-disease/2477754/Ocular Therapeutix announced that it has dosed the first patients in its phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” Michael Goldst
- Stoke Therapeutics Presents Preclinical Data on Potential Treatment For Inherited Optic Nerve Disorderhttps://modernod.com/news/stoke-therapeutics-presents-preclinical-data-on-potential-treatment-for-inherited-optic-nerve-disorder/2477751/Stoke Therapeutics announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells. OPA1 protein deficiency is the primary cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorde
- Tearlab Acquired by Accelmed Partners for $25 Millionhttps://modernod.com/news/tearlab-acquired-by-accelmed-partners-for-25-million/2477742/Private equity firm Accelmed Partners II (AP-II) has agreed to acquire TearLab for $25 million. The payment, which will be made over two tranches, will result in TearLab delisting from the “over the counter” OTCQB mar
- Optogenetic Gene Therapy Well Tolerated For Retinitis Pigmentosahttps://modernod.com/news/optogenetic-gene-therapy-well-tolerated-for-retinitis-pigmentosa/2477737/New findings presented on ARVOLearn showed that an optogenetic gene therapy was well tolerated in a group of patients with end-stage non-syndromic retinitis pigmentosa, according to a
- jCyte Enters Into Ex-US Licensing and Commercialization Agreement for jCell Therapy With Santenhttps://modernod.com/news/jcyte-enters-into-ex-us-licensing-and-commercialization-agreement-for-jcell-therapy-with-santen/2477727/jCyte Inc. announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the United States, in regions including Europe, Asia, and Japan. Under the terms of the licensing agreement, jC
- Hydroxychloroquine Fails to Help Hospitalized Coronavirus Patients in US Funded Studyhttps://modernod.com/news/hydroxychloroquine-fails-to-help-hospitalized-coronavirus-patients-in-us-funded-study/2477728/Hydroxychloroquine, a decades-old malaria drug, didn’t appear to help hospitalized patients with COVID-19, according to a new observational study published Thursday in the New England Journal of Medicine, according to a CN
- Insight Into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracyhttps://modernod.com/news/insight-into-fdas-revised-policy-on-antibody-tests-prioritizing-access-and-accuracy/2477725/In a blog post on the FDA website, agency leaders outlined a new policy that aims to provide more oversight of COVID-19 antibody tests. The revised policy on antibody tests was written by Anand Shah, MD, Deputy Commissioner for Medical and Scientific Affairs, and Jeff Shuren, MD, Director,
- Sight Sciences Introduces the Next-Generation Omni Surgical System for Microinvasive Glaucoma Surgeryhttps://modernod.com/news/sight-sciences-introduces-the-next-generation-omni-surgical-system-for-microinvasive-glaucoma-surgery/2477720/Sight Sciences announced the launch of its next-generation Omni Surgical System for microinvasive glaucoma surgery (MIGS) procedures. The Omni Surgical System combines two distinct angle procedures—ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS
- Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19https://modernod.com/news/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19/2477722/Sixty-four children and teens in New York State are suspected of having a mysterious inflammatory syndrome that is believed to be linked to COVID-19, the New York Department of Health said in an alert issued Wednesday, as
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-reports-new-data-with-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477713/Lineage Cell Therapeutics announced that updated results from a phase 1/2a study of its lead product candidate OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), were published online via th